Welcome to our dedicated page for ZIOP news (Ticker: ZIOP), a resource for investors and traders seeking the latest updates and insights on ZIOP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZIOP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZIOP's position in the market.
Alaunos Therapeutics (formerly Ziopharm Oncology) has opened enrollment for its Phase 1/2 TCR-T Library trial targeting KRAS, TP53, and EGFR mutations across six solid tumors. The IND was amended to include four additional TCRs, increasing patient eligibility. The company also has operationalized its in-house cGMP manufacturing facility to support clinical development. The name change reflects a renewed focus on TCR therapies, with trading under the new ticker symbol 'TCRT' beginning January 27, 2022.
Ziopharm Oncology (ZIOP) announced preclinical data at the Society for Immunotherapy of Cancer 2021 Annual Meeting regarding neoantigen-specific TCR-T cells targeting solid tumors. Utilizing its Sleeping Beauty technology, Ziopharm's TCR-T cells showed over 60% expression of neoantigen-specific TCRs. These cells effectively targeted tumor cells with specific mutations (EGFR, KRAS, p53) while minimizing off-target effects. The company plans to initiate a Phase 1/2 TCR-T Library trial in the first half of 2022, expanding its TCR library to increase eligible patient pools.
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) reported its financial results for Q3 2021, with a net loss of $22.7 million, or $0.11 per share, compared to a $20.3 million loss in Q3 2020. Research and development expenses increased to $14.5 million, up from $14.0 million in the same period last year, primarily due to restructuring costs. Ziopharm continues to develop its TCR-T Library program, with plans to initiate patient dosing in early 2022 and expand its library of TCRs. The company has approximately $91.7 million in cash reserves, expected to last until Q2 2023.
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) will report its third-quarter financial results for 2021 on November 8, 2021, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a corporate update. Investors can access the call by dialing the provided numbers or through a live webcast available on the company’s website. Ziopharm focuses on developing innovative T-cell receptor therapies using its proprietary Sleeping Beauty gene transfer platform and collaborates with leading cancer research institutions.
Ziopharm Oncology has announced a restructuring that includes a 60-person workforce reduction aimed at advancing its TCR-T Library program. These changes are expected to extend the company's cash runway into the first half of 2023. The first dosing of patients in the TCR-T Library Phase I/II clinical trial is anticipated in 1H2022, following delays linked to inadequate resources. The company remains committed to investing in internal manufacturing capabilities to facilitate accelerated patient dosing.
BOSTON and HOUSTON, Sept. 01, 2021 – Ziopharm Oncology, Inc. (Nasdaq: ZIOP) announced that CEO Kevin S. Boyle, Sr. will attend five virtual investor conferences in September 2021. Key dates include the Wells Fargo Virtual Healthcare Conference on September 9 at 10:00 am EDT, and the Cantor Virtual Global Healthcare Conference on September 28 at 3:20 pm EDT. Boyle aims to engage with shareholders and showcase Ziopharm’s advanced TCR science. Webcast access and recordings are available on the company’s website at ziopharm.com.
Ziopharm Oncology has appointed Kevin S. Boyle, Sr. as CEO, effective immediately, with a clear goal of enhancing shareholder value. Boyle brings over 20 years of leadership experience and a strong track record in capital management, having raised over $2 billion in equity and debt. Alongside Boyle's appointment, Raffaele Baffa MD, Ph.D. has been promoted to Head of Research and Development, while Adam Levy, Ph.D., MBA becomes Executive VP of Corporate Development and Investor Relations. The company plans to advance its TCR-T program and pursue partnerships to expand its oncology pipeline.
Ziopharm Oncology (ZIOP) achieved significant milestones in its TCR-T Library program, including the commissioning of its manufacturing facility and positive preclinical data. The company closed a $50 million venture debt financing with Silicon Valley Bank to extend its cash runway into Q4 2022. They plan to initiate patient dosing in their Phase I/II TCR-T Library trial in Q4 2021, targeting six solid tumor types. An update on the CD19 RPM CAR-T trial in Taiwan revealed no serious safety events but noted delays in patient infusions due to process development needs.
Ziopharm Oncology, Inc. (ZIOP) announced a conference call and webcast on August 9, 2021, at 4:30 p.m. EDT to discuss its second-quarter financial results ending June 30, 2021. The call can be accessed via phone or through a live webcast available on the company’s website. Ziopharm focuses on developing innovative non-viral and cytokine-driven cell and gene therapies aimed at treating cancer. Their strategy includes partnerships with prominent institutions like the National Cancer Institute and Regeneron Pharmaceuticals.
BOSTON, May 24, 2021 – Ziopharm Oncology, a clinical-stage biotech focused on cancer therapies, announced participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will be held June 1-4, with a fireside chat featuring Interim CEO Heidi Hagen and CMO Raffaele Baffa on June 4 at 1 PM ET. The Virtual Raymond James Human Health Innovations Conference is set for June 21-23, with Hagen speaking on June 22 at 2:40 PM ET. Webcasts of the presentations will be available on the company's website.
